Biotechnology

A Self-Reliant Future through HPV 9-Valent Vaccine Alliance: INNOVAX details Localization Strategy in Thailand at IPVS 2025

BANGKOK, Oct. 24, 2025 /PRNewswire/ -- On October 23, 2025, Dr. Zhiming ( Tiffany) Jiang, General Manager of Wantai Group, and Dr. Huirong (Harry) Pan, General Manager of Xiamen Innovax Biotech Co., Ltd. ("Innovax"), participated in the 37th International Papillomavirus Society (IPVS) Conference i...

2025-10-24 20:20 1475

Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infec...

2025-10-24 18:12 1818

Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore

* The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics inOctober 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNT...

2025-10-24 17:33 1209

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022

SUZHOU, China, Oct. 24, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of JSKN022, an independently developed innovative bispeci...

2025-10-24 12:56 1021

A New Era in Cervical Cancer Elimination: INNOVAX Presents Global Progress with HPV 9-Valent Vaccine on IPVS 2025 Opening Day

BANGKOK, Thailand, Oct. 23, 2025 /PRNewswire/ -- Xiamen Innovax Biotech Co., Ltd. ("INNOVAX") participated in the 37th International Papillomavirus Society (IPVS) Conference, and hosted a dedicated symposium titled "A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for ...

2025-10-23 23:24 1173

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (OD...

2025-10-23 20:15 730

Medison Strengthens its Global Commercialization Platform, Appoints Francis Wan as VP, GM Asia Pacific

With a strong track record across APAC, Francis Wan's appointment marks a powerful acceleration of Medison's growth in the region ZUG, Switzerland, Oct. 23, 2025 /PRNewswire/ -- Medison , the creator of a first-of-its-kind unified global commercialization platform...

2025-10-23 19:00 918

TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The Ame...

2025-10-23 19:00 997

FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease

TAIPEI, Oct. 23, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy'...

2025-10-23 11:24 1103

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153 Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for t...

2025-10-23 04:00 1275

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM's propriet...

2025-10-22 14:00 1796

ACROBiosystems and Partners Conclude OrganoAsia 2025

ACROBiosystems and Partners Conclude OrganoAsia 2025 - Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization TOKYO, Oct. 10, 2025 /PRNewswire/ -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystem...

2025-10-22 11:03 1953

ACROBiosystems and Partners Conclude OrganoAsia 2025

In the news release, ACROBiosystems and Partners Conclude OrganoAsia 2025, issued10-Oct-2025 by ACROBiosystems Group over PR Newswire, "Tokyo University of Science" in the paragraph starting with "The conference gathered leading specialists such as..." should read "Institute of Science Tokyo"....

2025-10-22 11:01 1803

NSG Bio Launches NSG BioSuites at Geneo - A New Product, Largest Site, and Fourth Location in Singapore

SINGAPORE, Oct. 21, 2025 /PRNewswire/ -- NSG Bio, a leading provider of flexible and high-quality biotech laboratory spaces, announced the launch of its latest product, NSG BioSuites, located at the brand-new Geneo development in Singapore Science Park. This marks NSG Bio's fourth site in Singapor...

2025-10-21 08:00 943

LabConnect Featured in Season Finale of Emmy-Nominated Series Tomorrow's World Today

JOHNSON CITY, Tenn., Oct. 21, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, will be featured on the season 9 finale of the innovation-focused TV series, Tomorrow's World Today. Premiering on Science Channel on November 8,...

2025-10-21 01:11 920

Benchling Partners with Anthropic to Build a Bridge Between Science and AI

Claude's Life Sciences Ecosystem pairs Benchling AI with advanced reasoning in Claude SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- Benchling today announced a partnership with ...

2025-10-21 00:00 1056

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

* After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). * OS was significantly longer with sac-TMT than with chemotherapy (H...

2025-10-20 17:06 1120

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions

LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances Accord B.V.'s commitment to improving global a...

2025-10-20 14:00 1109

Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth factor rece...

2025-10-20 13:59 933

Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colore...

2025-10-20 13:15 1107
12345678 ... 187